Prometheus Biosciences Inc (RXDX) Stock
RXDX is no longer traded. Prometheus Biosciences was acquired by Merck (MRK) on June 16, 2023.
Each RXDX share was exchanged for $200.00 in cash. Prices on this page are historical; the last trade was June 15, 2023 at $199.92.
See Merck (MRK) stock →Prometheus Biosciences stock price history
RXDX final trading statistics
- Final close
- $199.92
- Final trading day
- Jun 15, 2023
- Market cap at delisting
- $9.56B
- Shares outstanding
- 47.81M
- Final 52-week range
- $23.27 – $199.98
- Avg. volume (final 3 mo.)
- 1,238,351
- All-time high (split-adj.)
- $199.92 · Jun 2023
- All-time low (split-adj.)
- $4.25 · Nov 2016
- Return since IPO
- +1860.0%
- Beta
- -0.49
- Book value / share
- $14.62
- Price / book
- 13.67
Prometheus Biosciences annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2022 | $6.81M | -$137.1M | -$3.48 |
| FY2021 | $3.13M | -$91.5M | -$3.63 |
| FY2020 | $1.23M | -$37.1M | — |
| FY2019 | $1.12M | -$29.7M | — |
| FY2016 | — | -$103.6M | — |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Prometheus Biosciences Inc
Prometheus Biosciences, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of novel therapeutics for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease, as well as systemic sclerosis-associated interstitial lung disease. The company also develops PR300, a G-protein coupled receptor modulator for IBD and potentially other immune-mediated diseases; PRA052, an anti-CD30L mAb for IBD; PR1100, an anti-cytokine receptor mAb for IBD and other immune-mediated diseases; and PR2100, an anti-inflammatory cytokine mAb for IBD, and inflammatory and fibrotic diseases. It has a diagnostics development and collaboration agreement with Takeda Pharmaceutical Company Limited; co-development and manufacturing agreement with Dr. Falk Pharma GmbH for PRA052; license agreement with Cedars-Sinai Medical Center; and strategic collaboration with Millennium Pharmaceuticals, Inc. The company was formerly known as Precision IBD, Inc. and changed its name to Prometheus Biosciences, Inc. in October 2019. Prometheus Biosciences, Inc. was incorporated in 2016 and is headquartered in San Diego, California. As of June 16, 2023, Prometheus Biosciences, Inc. operates as a subsidiary of Merck & Co., Inc.
Prometheus Biosciences stock FAQ
What happened to Prometheus Biosciences stock?
Prometheus Biosciences was acquired by Merck (MRK) on June 16, 2023. Shareholders received $200.00 in cash for each share. RXDX stock stopped trading on the Nasdaq, with a final close of $199.92 on June 15, 2023.
What did Prometheus Biosciences shareholders receive?
Each RXDX share was converted into $200.00 in cash. The deal was valued at about $10.8 billion.
Is RXDX stock still trading?
No. RXDX was delisted from the Nasdaq on June 16, 2023 and no longer trades on a U.S. exchange.
What was the last price of RXDX stock?
RXDX closed at $199.92 on its final trading day, June 15, 2023, for a market value of about $9.56B.
What were Prometheus Biosciences's revenue and earnings in its last full fiscal year?
Prometheus Biosciences reported revenue of $6.81M and net income of -$137.1M in fiscal 2022, its last full year as a public company.
When did Prometheus Biosciences go public?
Prometheus Biosciences Inc stock began trading on March 12, 2021.